SG Americas Securities
DAWN

SG Americas Securities’s Day One Biopharmaceuticals DAWN Stock Holding History

SG Americas Securities’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.63M Sell
122,922
-227,170
-65% -$3.2M ﹤0.01% 1268
2025
Q4 		$3.26M Buy
350,092
+323,747
+1,229% +$2.7M ﹤0.01% 1284
2025
Q3 		$186K Buy
+26,345
New +$181K ﹤0.01% 2786
2025
Q2 		– Sell
-34,409
Closed -$273K – 3079
2025
Q1 		$273K Sell
34,409
-33,965
-50% -$366K ﹤0.01% 2290
2024
Q4 		$866K Buy
+68,374
New +$951K ﹤0.01% 931
2024
Q3 		– Sell
-8,222
Closed -$113K – 3453
2024
Q2 		$113K Buy
+8,222
New +$120K ﹤0.01% 2476
2024
Q1 		– Sell
-64,692
Closed -$945K – 3065
2023
Q4 		$945K Buy
64,692
+27,712
+75% +$336K 0.01% 1057
2023
Q3 		$454K Buy
36,980
+13,683
+59% +$178K 0.01% 1838
2023
Q2 		$278K Buy
23,297
+6,140
+36% +$80.2K ﹤0.01% 1646
2023
Q1 		$229K Buy
17,157
+4,018
+31% +$78.5K ﹤0.01% 2325
2022
Q4 		$283K Buy
13,139
+3,519
+37% +$72.2K ﹤0.01% 1966
2022
Q3 		$193K Buy
9,620
+174
+2% +$3.7K ﹤0.01% 2354
2022
Q2 		$169K Buy
+9,446
New +$97.5K ﹤0.01% 2784

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

SG Americas Securities's DAWN Position: Q1 2026 in Review

SG Americas Securities reduced its Day One Biopharmaceuticals (DAWN) stake by 65% in Q1 2026, selling an estimated $3.2M and leaving 122,922 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

SG Americas Securities first reported a position in DAWN in Q2 2022 and has held it in 13 quarters since. The position peaked at $3.26M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • SG Americas Securities held 122,922 shares of Day One Biopharmaceuticals worth $2.63M as of Q1 2026.
  • SG Americas Securities sold 227,170 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.2M.
  • Day One Biopharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1268 holding.
  • SG Americas Securities first reported a position in Day One Biopharmaceuticals in Q2 2022 and has held it in 13 quarters since.
  • SG Americas Securities's Day One Biopharmaceuticals position peaked at $3.26M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.